Yuning Song

Dr. Yuning Song

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 July 2024 in Medcomm
Verified
Journal Article
Open access
XWXinyu Wu
Xinyu Wu
JYJie Yang
Jie Yang
JZJiayao Zhang
Jiayao Zhang
YSYuning Song
Yuning Song
The development of gene editing tools has been a significant area of research in the life sciences for nearly 30 years. These tools have been widely utilized in disease detection and mechanism research. In the new century, they have shown potential in addressing various scientific challenges and saving lives through gene editing therapies, particularly in combating cardiovascular disease (CVD). The rapid advancement of gene editing therapies has provided optimism for CVD patients. The progress of gene editing therapy for CVDs is a comprehensive reflection of the practical implementation of gene editing technology in both clinical and basic research settings, as well as the steady advancement of research and treatment of CVDs. This article provides an overview of the commonly utilized DNA‐targeted gene editing tools developed thus far, with a specific focus on the application of these tools, particularly the clustered regularly interspaced short palindromic repeat/CRISPR‐associated genes (Cas) (CRISPR/Cas) system, in CVD gene editing therapy. It also delves into the challenges and limitations of current gene editing therapies, while summarizing ongoing research and clinical trials related to CVD. The aim is to facilitate further exploration by relevant researchers by summarizing the successful applications of gene editing tools in the field of CVD.

24 May 2023 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
JYJie Yang
Jie Yang
XWXinyu Wu
Xinyu Wu
YSYuning Song
Yuning Song

16 September 2022 in Science China Life Sciences
Verified
Journal Article
Closed access
PDF file
ZZZhongtian Zhang
Zhongtian Zhang
XWXinyu Wu
Xinyu Wu
JYJie Yang
Jie Yang
XLXin Liu
Xin Liu
RLRuonan Liu
Ruonan Liu
YSYuning Song
Yuning Song

2 May 2023 in Neurobiology of Disease
Verified
Journal Article
Open access
XLXin Liu
Xin Liu
JYJie Yang
Jie Yang
ZLZhaoyi Li
Zhaoyi Li
RLRuonan Liu
Ruonan Liu
XWXinyu Wu
Xinyu Wu
YSYuning Song
Yuning Song
Primary microcephaly (PMCPH) is a rare autosomal recessive neurodevelopmental disorder with a global prevalence of PMCPH ranging from 0.0013% to 0.15%. Recently, a homozygous missense mutation in YIPF5 (p. W218R) was identified as a causative mutation of severe microcephaly. In this study, we constructed a rabbit PMCPH model harboring YIPF5 (p.W218R) mutation using SpRY-ABEmax mediated base substitution, which precisely recapitulated the typical symptoms of human PMCPH. Compared with wild-type controls, the mutant rabbits exhibited stunted growth, reduced head circumference, altered motor ability, and decreased survival rates. Further investigation based on model rabbit elucidated that altered YIPF5 function in cortical neurons could lead to endoplasmic reticulum stress and neurodevelopmental disorders, interference of the generation of apical progenitors (APs), the first generation of progenitors in the developing cortex. Furthermore, these YIPF5- mutant rabbits support a correlation between unfolded protein responses (UPR) induced by endoplasmic retic-ulum stress (ERS), and the development of PMCPH, thus providing a new perspective on the role of YIPF5 in human brain development and a theoretical basis for the differential diagnosis and clinical treatment of PMCPH. To our knowledge, this is the first gene-edited rabbit model of PMCPH. The model better mimics the clinical features of human microcephaly than the traditional mouse models. Hence, it provides great potential for un-derstanding the pathogenesis and developing novel diagnostic and therapeutic approaches for PMCPH.

27 October 2022 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
YZYuxin Zhang
Yuxin Zhang
JYJie Yang
Jie Yang
HYHaobin Yao
Haobin Yao
ZZZhongtian Zhang
Zhongtian Zhang
YSYuning Song
Yuning Song
Family with sequence similarity 83 members H (Fam83h) is essential for dental enamel formation. Fam83h mutations cause human amelogenesis imperfecta (AI), an inherited disorder characterized by severe hardness defects in dental enamel. Nevertheless, previous studies showed no enamel defects in Fam83h-knockout/lacZ-knockin mice. In this study, a large deletion of the Fam83h gene (900 bp) was generated via a dual sgRNA-directed CRISPR/Cas9 system in rabbits. Abnormal tooth mineralization and loose dentine were found in homozygous Fam83h knockout (Fam83h(-/-)) rabbits compared with WT rabbits. In addition, reduced hair follicle counts in dorsal skin, hair cycling dysfunction and hair shaft differentiation deficiency were observed in Fam83h(-/-) rabbits. Moreover, X-rays and staining of bone sections showed abnormal bending of the ulna and radius and an ulnar articular surface with insufficient trabecular bone in Fam83h(-/-) rabbits. Taken together, these data are the first report of defective hair cycling, hair shaft differentiation and abnormal bending of the ulna and radius in Fam83h(-/-) rabbits. This novel Fam83h(-/-) rabbit model may facilitate understanding the function of Fam83h and the pathogenic mechanism of the Fam83h mutation.

30 July 2024 in EMBO Molecular Medicine
Verified
Journal Article
Open access
XWXinyu Wu
Xinyu Wu
RLRuonan Liu
Ruonan Liu
ZZZhongtian Zhang
Zhongtian Zhang
JYJie Yang
Jie Yang
XLXin Liu
Xin Liu
ZLZhanjun Li
Zhanjun Li
Cerebral palsy (CP) is a prevalent neurological disorder that imposes a significant burden on children, families, and society worldwide. Recently, the RhoB p.S73F mutation was identified as a de novo mutation associated with CP. However, the mechanism by which the RhoB p.S73F mutation causes CP is currently unclear. In this study, rabbit models were generated to mimic the human RhoB p.S73F mutation using the SpG-BE4max system, and exhibited the typical symptoms of human CP, such as periventricular leukomalacia and spastic-dystonic diplegia. Further investigation revealed that the RhoB p.S73F mutation could activate ACAT1 through the LYN pathway, and the subsequently altered lipid levels may lead to neuronal and white matter damage resulting in the development of CP. This study presented the first mammalian model of genetic CP that accurately replicates the RhoB p.S73F mutation in humans, provided further insights between RhoB and lipid metabolism, and novel therapeutic targets for human CP.